Dovitinib Dilactic acid (TKI258 Dilactic acid) is a highly potent, novel multitargeted growth factor receptor kinase inhibitor with IC50 of 1, 2, 10, 8, 27, 36 nM for FLT3, c-KIT, VEGFR1/2/3, PDGFRß and CSF-1R, respectively. It shows both antitumor and antiangiogenic activities in vivo.It potently inhibits FGFR3 with an inhibitory concentration of 50% (IC50) of 5 nM in in vitro kinase assays and selectively inhibited the growth of B9 cells and human myeloma cell lines expressing wild-type (WT) or activated mutant FGFR3. Antiproliferative activity of Dovitinib Dilactic acid (TKI258 Dilactic acid) against MV4;11 was ~24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.

June 21, 2017

prudect name : Dovitinib Dilactic acid (TKI258 Dilactic acid) is a highly potent, novel multitargeted growth factor receptor kinase inhibitor with IC50 of 1, 2, 10, 8, 27, 36 nM for FLT3, c-KIT, VEGFR1/2/3, PDGFRß and CSF-1R, respectively. It shows both antitumor and antiangiogenic activities in vivo.It potently inhibits FGFR3 with an inhibitory concentration of 50% (IC50) of 5 nM in in vitro kinase assays and selectively inhibited the growth of B9 cells and human myeloma cell lines expressing wild-type (WT) or activated mutant FGFR3. Antiproliferative activity of Dovitinib Dilactic acid (TKI258 Dilactic acid) against MV4;11 was ~24-fold greater compared with RS4;11, indicating more potent inhibition against cells with constitutively activated FLT3 ITD.
dovitinib lactate

Synonyms: TKI258 Dilactic acidCAS NO: 915769-50-5Molecular Formula: C₂₁H₂₁FN₆O.C₃H₆O₃.H₂OMolecular Weight: 500.53Purity: 98% minSolubility: In DMSOStorage: −20°C

JTC 801 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18511095